Literature DB >> 8914022

Heparin and heparinoids prevent the binding of immune complexes containing nucleosomal antigens to the GBM and delay nephritis in MRL/lpr mice.

M C van Bruggen1, B Walgreen, T P Rijke, M J Corsius, K J Assmann, R J Smeenk, G W van Dedem, K Kramers, J H Berden.   

Abstract

Monoclonal anti-nucleosome antibodies (mAbs) complexed to nucleosomal antigens can bind to DNA and to heparan sulfate (HS) in ELISA and to the GBM in vivo in a rat renal perfusion system, whereas non-complexed mAbs do not bind [1]. In this study, we analyzed whether heparin (HEP) or N-desulfated/acetylated heparins (DSA-HEP), structurally and functionally strongly related to HS, are able to prevent the binding of these complexed mAbs to DNA and to HS in vitro and to rat GBM in vivo. In ELISA the binding of nucleosome complexed antinucleosome antibodies to DNA and HS was inhibited dose-dependently by HEP, DSA-HEP and low molecular weight (LMW) DSA-HEP. Intravenous injection of nucleosome/anti-nucleosome immune complexes without heparin/heparinoids in BALB/c mice led to GBM binding, while simultaneous injection of heparin/heparinoids with complexed antibodies or pretreatment with heparin subcutaneously prior to injection of complexes prevented this binding. Subsequently, we tested the preventive effect of HEP, DSA-HEP and LMW-DSA-HEP on progression of renal disease in MRL/lpr mice. Treatment was started at an age of eight weeks in a dose of 50 micrograms daily. With all three drugs albuminuria was significantly delayed compared to PBS treated controls (cumulative incidence of proteinuria at 20 weeks in controls 60% vs. 13%, 14% and 6% respectively for HEP, DSA-HEP and LMW-DSA-HEP; P < 0.05). At week 21 the glomerulonephritis was histologically less severe in heparin/heparinoid treated animals (P = 0.02). In immunofluorescence the amount of immunoglobulin and C3 deposits in the glomerular capillary wall tended to be less in heparin/heparinoid treated mice compared to PBS treated controls (P = 0.07). Furthermore, at 20 weeks anti-HS levels in plasma of heparin/heparinoid treated mice were significantly lower (P < 0.05). We conclude that interaction of heparin or heparin analogs with HS reactive immune complexes containing nucleosomal antigens prevents the binding of these immune complexes to the GBM and delays nephritis in MRL/lpr mice.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8914022     DOI: 10.1038/ki.1996.471

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  8 in total

Review 1.  Structural modification of DNA--a therapeutic option in SLE?

Authors:  Steffen Frese; Betty Diamond
Journal:  Nat Rev Rheumatol       Date:  2011-10-18       Impact factor: 20.543

2.  Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays.

Authors:  Quan-Zhen Li; Quan Li Zhen; Chun Xie; Tianfu Wu; Meggan Mackay; Cynthia Aranow; Chaim Putterman; Chandra Mohan
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

Review 3.  Anti-DNA, antihistone, and antinucleosome antibodies in systemic lupus erythematosus and drug-induced lupus.

Authors:  G Q Shen; Y Shoenfeld; J B Peter
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

4.  Identification of tubular heparan sulfate as a docking platform for the alternative complement component properdin in proteinuric renal disease.

Authors:  Azadeh Zaferani; Romain R Vivès; Pieter van der Pol; Jelleke J Hakvoort; Gerjan J Navis; Harry van Goor; Mohamed R Daha; Hugues Lortat-Jacob; Marc A Seelen; Jacob van den Born
Journal:  J Biol Chem       Date:  2010-12-06       Impact factor: 5.157

Review 5.  The Role of Anti-DNA Antibodies in the Development of Lupus Nephritis: A Complementary, or Alternative, Viewpoint?

Authors:  Beatrice Goilav; Chaim Putterman
Journal:  Semin Nephrol       Date:  2015-09       Impact factor: 5.299

Review 6.  Chromatin as a target antigen in human and murine lupus nephritis.

Authors:  Annica Hedberg; Elin Synnøve Mortensen; Ole Petter Rekvig
Journal:  Arthritis Res Ther       Date:  2011-04-18       Impact factor: 5.156

7.  LMW heparin prevents increased kidney expression of proinflammatory mediators in (NZBxNZW)F1 mice.

Authors:  Annica Hedberg; Premasany Kanapathippillai; Ole Petter Rekvig; Kristin Andreassen Fenton
Journal:  Clin Dev Immunol       Date:  2013-09-17

Review 8.  Therapy of systemic lupus erythematosus: a look into the future.

Authors:  Josef S Smolen
Journal:  Arthritis Res       Date:  2002-05-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.